Quarterly ResultJul 14, 2026, 04:03 PM
Kestra Medical Q4 Revenue +66% to $28.6M; FY27 Guidance $137M
AI Summary
Kestra Medical Technologies reported strong financial results for the fourth quarter and fiscal year ended April 30, 2026. Fiscal 4Q26 revenue grew 66% to $28.6 million, and full-year 2026 revenue increased 59% to $95.1 million. The company also saw significant gross margin expansion, reaching 54.8% in Q4 and 51.4% for the full year. Kestra provided optimistic FY27 revenue guidance of $137 million, projecting 44% growth, driven by market expansion and operational achievements.
Key Highlights
- Fiscal 4Q26 revenue increased 66% to $28.6 million.
- FY26 revenue increased 59% to $95.1 million.
- Fiscal 4Q26 gross margin expanded to 54.8% from 44.3% year-over-year.
- FY26 gross margin expanded to 51.4% from 40.5% year-over-year.
- GAAP net loss for Fiscal 4Q26 was $38.8 million, compared to $51.1 million in prior year.
- GAAP net loss for FY26 was $131.6 million, compared to $113.8 million in FY25.
- 6,357 ASSURE® system prescriptions in Fiscal 4Q26, up 63% year-over-year.
- FY27 revenue guidance set at $137 million, representing 44% growth.
Price Impact
More from KMTS